[go: up one dir, main page]

AR130287A1 - METHODS FOR THE MANUFACTURE OF KINASE INHIBITORS - Google Patents

METHODS FOR THE MANUFACTURE OF KINASE INHIBITORS

Info

Publication number
AR130287A1
AR130287A1 ARP230102240A ARP230102240A AR130287A1 AR 130287 A1 AR130287 A1 AR 130287A1 AR P230102240 A ARP230102240 A AR P230102240A AR P230102240 A ARP230102240 A AR P230102240A AR 130287 A1 AR130287 A1 AR 130287A1
Authority
AR
Argentina
Prior art keywords
methods
manufacture
kinase inhibitors
disclosure provides
tnik
Prior art date
Application number
ARP230102240A
Other languages
Spanish (es)
Inventor
Xing Liang
Hua Cao
Xin Cheng
Luoheng Qin
Original Assignee
Insilico Medicine Ip Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insilico Medicine Ip Ltd filed Critical Insilico Medicine Ip Ltd
Publication of AR130287A1 publication Critical patent/AR130287A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En un aspecto, la descripción proporciona métodos para sintetizar inhibidores de quinasas TNIK y/o MAP4K4 para el tratamiento de la enfermedad. En un aspecto, la descripción proporciona compuestos intermedios usados en los métodos de síntesis descritos en la presente. Un método para producir un compuesto representado por la fórmula (1), o una sal farmacéuticamente aceptable del mismo.In one aspect, the disclosure provides methods for synthesizing inhibitors of TNIK and/or MAP4K4 kinases for the treatment of disease. In one aspect, the disclosure provides intermediate compounds used in the synthesis methods described herein. A method for producing a compound represented by formula (1), or a pharmaceutically acceptable salt thereof.

ARP230102240A 2022-08-24 2023-08-23 METHODS FOR THE MANUFACTURE OF KINASE INHIBITORS AR130287A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2022114447 2022-08-24

Publications (1)

Publication Number Publication Date
AR130287A1 true AR130287A1 (en) 2024-11-20

Family

ID=90012561

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230102240A AR130287A1 (en) 2022-08-24 2023-08-23 METHODS FOR THE MANUFACTURE OF KINASE INHIBITORS

Country Status (9)

Country Link
EP (1) EP4577524A1 (en)
JP (1) JP2025527659A (en)
KR (1) KR20250051740A (en)
CN (1) CN119923387A (en)
AR (1) AR130287A1 (en)
AU (1) AU2023327885A1 (en)
CA (1) CA3265130A1 (en)
TW (1) TW202416964A (en)
WO (1) WO2024041555A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202517635A (en) * 2023-07-06 2025-05-01 香港商英矽智能科技知識產權有限公司 Crystalline tnik inhibitor and uses thereof
WO2025016302A1 (en) * 2023-07-14 2025-01-23 Insilico Medicine Ip Limited Pharmaceutical formulations for inhalation and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040468A1 (en) * 2000-11-16 2002-05-23 Smithkline Beecham Corporation Compounds
US6787555B2 (en) * 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
WO2010127152A2 (en) * 2009-04-29 2010-11-04 Irm Llc Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
US11795160B2 (en) * 2019-02-22 2023-10-24 Insilico Medicine Ip Limited Kinase inhibitors
WO2022179529A1 (en) * 2021-02-24 2022-09-01 Insilico Medicine Ip Limited Analogs for the treatment of disease
EP4298093A4 (en) * 2021-02-24 2025-08-06 Insilico Medicine Ip Ltd Analogs for the treatment of disease

Also Published As

Publication number Publication date
CA3265130A1 (en) 2024-02-29
EP4577524A1 (en) 2025-07-02
AU2023327885A1 (en) 2025-03-06
TW202416964A (en) 2024-05-01
KR20250051740A (en) 2025-04-17
JP2025527659A (en) 2025-08-22
CN119923387A (en) 2025-05-02
WO2024041555A1 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
AR130287A1 (en) METHODS FOR THE MANUFACTURE OF KINASE INHIBITORS
CL2024002874A1 (en) Kras inhibitors
CO2021010415A2 (en) Jak inhibitor and method of preparation thereof
MX2022012306A (en) CHROMENONE ALLOSTERIC INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES.
DOP2021000254A (en) PYRROLIDINE COMPOUNDS
CL2021002244A1 (en) Jak inhibitor compound and use thereof
MX2021011606A (en) Compounds targeting prmt5.
CO2025013134A2 (en) Kras inhibitors
AR126251A1 (en) CDK2 INHIBITORS
MX2025011447A (en) KRAS INHIBITORS
EA202193015A1 (en) CDK INHIBITORS
CR20190124A (en) Amino pyrimidine ssao inhibitors
CL2024002623A1 (en) Solid forms, salts and preparation processes of a cdk2 inhibitor.
CL2023001367A1 (en) btk inhibitors
AR128500A1 (en) DHX9 RNA HELICase INHIBITORS AND USES THEREOF
AR126849A1 (en) QUINAZOLINE COMPOUNDS FOR DISEASE TREATMENT
MX2023014466A (en) Pyridopyrimidine derivatives useful as wee1 kinase inhibitors.
CL2025000672A1 (en) Aminopyrimidine derivatives, CDK2 inhibitors; pharmaceutical composition; use for treating cancer.
CL2025001257A1 (en) Process for the production of substituted morpholine derivatives
UY39799A (en) Pyrrolyl–sulfonamide compounds
MX2022002941A (en) 1,3,5-TRIAZINE DERIVATIVE CRYSTAL OR SOLVATE THEREOF AND METHOD FOR PRODUCING THE SAME.
MX2023001438A (en) Formulations of triphenyl calcilytic compounds.
AR126196A1 (en) PROCESS TO PREPARE EGFR INHIBITORS
CO2025016753A2 (en) gsk3α inhibitors and methods of their use
AR129185A1 (en) 6-(PYRIMIDIN-4-YL)QUINOLINE COMPOUNDS SUBSTITUTED AS CYCLIN-DEPENDENT KINASE INHIBITORS